DaltonTx

At DaltonTx, we are redefining how technology powers drug discovery — creating the intelligence engine behind tomorrow’s medicines. Our adaptive, AI-enabled platforms give pharma, biotech, and CROs the intelligence backbone modern R&D cannot move forward without. Purpose-built for small molecules and biologics, our technology integrates seamlessly into scientific workflows, learns from every experiment, and accelerates the path from idea to medicine. Unlike traditional project-based models, DaltonTx provides lasting capability: collaborative systems that combine machine learning, software en... At DaltonTx, we are redefining how technology powers drug discovery — creating the intelligence engine behind tomorrow’s medicines. Our adaptive, AI-enabled platforms give pharma, biotech, and CROs the intelligence backbone modern R&D cannot move forward without. Purpose-built for small molecules and biologics, our technology integrates seamlessly into scientific workflows, learns from every experiment, and accelerates the path from idea to medicine. Unlike traditional project-based models, DaltonTx provides lasting capability: collaborative systems that combine machine learning, software engineering, and deep drug discovery expertise. The result is technology that learns from every scientist, model, and experiment — guiding better decisions, evolving with your science, and helping you deliver breakthrough therapies to patients faster. Founded by scientists for scientists, DaltonTx brings together decades of real-world experience in drug discovery, software engineering, and AI. The team — Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley, and Professor Charlotte Deane MBE — has built pioneering AI discovery platforms at AstraZeneca and Exscientia, while also drawing on world-leading academic research from the University of Oxford. This unique combination of industry execution and academic excellence positions DaltonTx at the forefront of AI-enabled drug discovery.

In the news